Wondering Why Everest Medicines Fell? What The Bears Saw
If you only glanced at the headlines on Everest Medicines this year, a stream of licensing deals, portfolio additions and an interim move toward breakeven might have sounded reassuring. For Everest Medicines shareholders, the loss over the past year was 36.3%, including dividends. If you had been weighing a position 12 months ago, how much of that setback was already hinted at in the mix of bull and bear expectations that were on record?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
The move put Everest Medicines in the middle of this trade. Scan 122 healthcare AI stocks for other companies exposed to it.
The Two Stories Around Everest Medicines At The Time
The shares cost HK$51.05 at the start of the period, and Everest Medicines sat between two very different yet reasonable stories about where it might go next.
On the optimistic side, the bullish Narrative set Fair Value at HK$62.67, built on fast revenue growth of 62.3% and profit margins rising to 21.2% as NEFECON and VELSIPITY gained ground across China and Asia-Pacific.
The bearish view pinned Fair Value at HK$25.58, accepting 53.9% revenue growth and a 22.1% margin assumption but stressing Chinese pricing pressure and higher regulatory hurdles as key threats.
What The Everest Medicines Results Actually Tested
The clearest new fact was Everest Medicines reducing its H1 loss from CNY 249.79 million to CNY 5.944 million while net margin moved from a 56.0% loss to a 0.5% loss. Revenue was CNY 1,147.84 million in H1 2026 versus CNY 446.123 million a year earlier, which supported the bullish demand story but left the profit margin target still unproven. Overall, the evidence pointed in both directions.
The core assumption here was that high top line growth would quickly translate into strong, positive profitability. When you test a similar claim elsewhere, track both the loss or profit level and the net margin line, not just the revenue figure or headline growth rate.
What Today's Everest Medicines Price Is Asking You To Believe
Everest Medicines now trades at HK$33.8. The selected Narrative sets its Fair Value above that level and anchors the argument in profitability, multi-franchise breadth and the use of out-licensing alongside in-house development.
The key assumption a buyer needs to test is that Everest can convert its renal and cardiovascular franchises, plus early mRNA oncology work, into sustained earnings from multiple therapies.
"A key requirement is Everest Medicines executing on its plan to turn its growing renal and cardiovascular portfolios, expanding A2MS commercial network, and mRNA oncology programs into sustained product launches and durable hospital coverage across Greater China and wider Asia."
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there
Everest Medicines And A Parallel Path
Looking at Everest Medicines, you may already be weighing drug pipelines and approval risk. Alongside it, another business faces a similar hurdle in a different corner of therapeutics.
This company is focused on obesity and cardiometabolic treatments, especially a pill version of a key therapy. Management is scaling manufacturing and distribution to meet potential prescription demand.
The same group is also developing blood and endocrine medicines that could diversify its earnings base beyond weight loss drugs. AI tools are pushing more early stage trials into that pipeline.
If these programs keep moving forward and launches resonate, this parallel story stays compelling. The tension between planned capacity and actual prescription demand remains the unresolved hinge.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 19% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com